CTN 327: Impact of COVID-19 on persons with HIV in Canada
The impact of COVID-19 on persons with HIV in Canada: Data from the HIV/HCV co-infection/CCC (CTN 222) and HIV aging cohorts (CTN 314)
About the Study
CTN 327 will explore the effects of COVID-19 on people living with HIV or both HIV and hepatitis C virus (HCV). The study will look at the experiences of people during the pandemic and their satisfaction with virtual care. It will also test whether participants have had COVID-19 (with or without symptoms) and catalogue the severity of the disease.
Background
COVID-19 has had significant effects on marginalized communities, including people living with HIV. People living with HIV, or both HIV and HCV, have faced unique challenges and disruptions related to the pandemic. While these clinical, social, and economic effects have been studied in some populations, they have not been adequately studied in Canadians living with HIV.
Study Approach
CTN 327 is a sub-study of CTN 222 and CTN 314, and aims to enrol 1,000 participants from those pre-existing cohorts. Study participants will be asked to complete three visits over 18 months as part of the sub-study; these visits will coincide with the scheduled visits for the parent studies (CTN 222 or 314).
During these visits, participants will complete a questionnaire on routine HIV care, emotional and mental wellbeing, satisfaction with virtual care, and COVID-19 symptoms. For participants in CTN 314, an additional tube of blood will be drawn during their visits, while CTN 222 participants will not need to provide additional blood beyond what is regularly collected. This blood will be tested for COVID-19 antibodies. Participants will receive their COVID-19 test results when they become available.
Eligibility Requirements
Required
All people living with HIV/HCV who are enrolled in CTN 222 are eligible to participate in this sub-study. These participants meet the following criteria:
- Age >16 years old (i.e., adults, may vary according to provincial criteria)
- HIV seropositive
- HCV infected or evidence of exposure
- Able to provide informed consent
All persons enrolled in CTN 314 are eligible to participate in this sub-study. These participants meet the following criteria:
- HIV-1 positive
- ≥65 years of age
- Able to communicate sufficiently in English or French to consent and complete study procedures
Not allowed
- Not meeting inclusion criteria for CTN 222 or CTN 314
Investigators
Here’s who is leading this study.
If you would like to take part in this study or want more information, please contact:
CTN 222 Study Coordinator
Isabelle Robichaud
Isabelle.robichaud@muhc.mcgill.ca
514-934-1934 ext. 32221
CTN 314 Study Coordinator
Lianne Thai
lianne.thai@uhn.ca
416-314-4800 ext. 2240
Participating Sites
Southern Alberta Clinic
- Calgary, AB
SHARE University of Saskatchewan
- Saskatoon, SK
Regina General Hospital
- Regina, SK
Oak Tree Clinic
- Vancouver, BC
Vancouver Infectious Disease Center
- Vancouver, BC
Native Bc Health Center, St. Paul’s Hospital
- Vancouver, BC
BC Centre for Excellence in HIV/AIDS, St. Paul’s Hospital
- Vancouver, BC
MC Master University Medical Centre
- Hamilton, ON
The HAVEN/Hemophilia Progra HRSRH
- Sudbury, ON
Toronto General Hospital, Infectious Disease Division
- Toronto, ON
Windsor Regional Hospital
- Windsor, ON
The Ottawa Hospital – General Campus
- Ottawa, ON
Research Institute of McGill University Health Centre
- Montreal, QC
CHUM – Hôtel-Dieu
- Montréal, QC
Royal Victoria Hospital (former MCI)
- Montréal, QC
CHU de Québec-Université Laval
- Montréal, QC
Clinique Médicale du Quartier Latin
- Montréal, QC
Queen Elizabeth II Health Sciences Centre
- Halifax, NS
- Site Investigator
-
12345 Street Name,
City Name, BC V3M 9J3
- Contact Person
- contact@email.com
- 1 (604) 555-9999
- Site Investigator
-
12345 Street Name,
City Name, BC V3M 9J3
- Contact Person
- contact@email.com
- 1 (604) 555-9999